Baird downgraded Carisma Therapeutics (CARM) to Neutral from Outperform with a price target of $1, down from $10. Carisma earlier this week announced plans to undergo a strategic restructuring, shifting its focus from its lead HER2 ex vivo CAR-M program, CT-0525, toward in vivo pipeline programs, the analyst tells investors in a research note. The firm believes it is likely 12 months before the first internal in vivo program enters the clinic, and is downgrading the shares given the lack of near-term catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Carisma Therapeutics downgraded to Neutral from Buy at BTIG
- Carisma Therapeutics price target lowered to $12 from $24 at D. Boral Capital
- Carisma Therapeutics announces restructuring, 34% workforce reduction
- Carisma Therapeutics Restructures Amid Strategic Refocus